Targeson develops, manufactures, and markets acoustically active microspheres for the medical research market. It's research tools include ultrasound contrast agents for molecular imaging, and targetable gene transfection agents.
Wash-in and accumulation of Visistar VCAM-1 in plaque-containing arteries in mouse model of atherosclerosis.
Targeson’s ultrasound contrast agents include:
Targestar® P Perfusion contrast agent to enhance and quantify blood flow and vascular function for use in ultrasound scanner in the 1-15 MHz range .
Targestar P-HF Perfusion contrast agent for use with high frequency scanners for blood flow and vascular function for use in ultrasound scanner in the 15-40 MHz range .
Targestar SA Targetable contrast agent enabling a one-step conjugation of any biotinylated ligand to be coupled to a microsphere suitable for a wide variety of molecular imaging applications.
Visistar® Integrin Targeted contrast agent that binds endothelial avB3 integrin for imaging angiogenesis and tumor growth.
Visistar VEGFR2 Targeted contrast agent with a VEGFR2 binding ligand for imaging angiogenesis and tumor growth.
Visistar VCAM-1 Targeted contrast agent to VCAM-1 for molecular imaging of inflammation.
Targeson gene transfection agents include:
Targesphere® Targetable gene delivery agent used for in vivo and organ specific in vitro transfection.
Targesphere® SA Targetable gene delivery agent enabling one-step conjugation of any biotinylated ligand to allow cell specific in vivo transfection.
Targestar®, Visistar®, and Targesphere®, are registered trademarks, and LipisphereTM and TargeSepTM are pending trademarks of Targeson, Inc.